Abdullahi, A;
Oladele, D;
Owusu, M;
Kemp, SA;
Ayorinde, J;
Salako, A;
Fink, D;
... Gupta, RK; + view all
(2022)
SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa.
Nature Communications
, 13
, Article 6131. 10.1038/s41467-022-33792-x.
Preview |
Text
s41467-022-33792-x.pdf - Published Version Download (2MB) | Preview |
Abstract
Real-world data on vaccine-elicited neutralising antibody responses for two-dose AZD1222 in African populations are limited. We assessed baseline SARS-CoV-2 seroprevalence and levels of protective neutralizing antibodies prior to vaccination rollout using binding antibodies analysis coupled with pseudotyped virus neutralisation assays in two cohorts from West Africa: Nigerian healthcare workers (n = 140) and a Ghanaian community cohort (n = 527) pre and post vaccination. We found 44 and 28% of pre-vaccination participants showed IgG anti-N positivity, increasing to 59 and 39% respectively with anti-receptor binding domain (RBD) IgG-specific antibodies. Previous IgG anti-N positivity significantly increased post two-dose neutralizing antibody titres in both populations. Serological evidence of breakthrough infection was observed in 8/49 (16%). Neutralising antibodies were observed to wane in both populations, especially in anti-N negative participants with an observed waning rate of 20% highlighting the need for a combination of additional markers to characterise previous infection. We conclude that AZD1222 is immunogenic in two independent West African cohorts with high background seroprevalence and incidence of breakthrough infection in 2021. Waning titres post second dose indicates the need for booster dosing after AZD1222 in the African setting despite hybrid immunity from previous infection.
Type: | Article |
---|---|
Title: | SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1038/s41467-022-33792-x |
Publisher version: | https://doi.org/10.1038/s41467-022-33792-x |
Language: | English |
Additional information: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
URI: | https://discovery.ucl.ac.uk/id/eprint/10183372 |



1. | ![]() | 61 |
2. | ![]() | 15 |
3. | ![]() | 9 |
4. | ![]() | 7 |
5. | ![]() | 5 |
6. | ![]() | 5 |
7. | ![]() | 3 |
8. | ![]() | 3 |
9. | ![]() | 3 |
10. | ![]() | 2 |
Archive Staff Only
![]() |
View Item |